Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Erdem GÖKER"'
Autor:
Patrick Forde, Neru Munshi, Ugur Sahin, Oezlem Tuereci, Akin Atmaca, Petra Rietschel, Dániel Deme, Bala Öven, Erdem Göker, Istvan Lang, Patrick Brück, Michael Wenger, Thomas Schell, Kezi Ünsal-Kaçmaz, Janet Markman, Huyuan Yang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/8417f9713f3d4d198f686b47521e32ce
Autor:
Glenwood D. Goss, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Dolores Isla, Alessandro Morabito, Young J. Min, Andrea Ardizzoni, Shaun Bender, Agnieszka Cseh, Enriqueta Felip
Publikováno v:
EClinicalMedicine, Vol 37, Iss , Pp 100940- (2021)
Background: LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung. We report the final overall survival (OS) and safety ana
Externí odkaz:
https://doaj.org/article/d8fe0d7fea454b01b8c9f6bcd8ec32f9
Autor:
Jean-Charles Soria, Enriqueta Felip, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Wei Li, Dolores Isla, Salih Z Guclu, Alessandro Morabito, Young J Min, Andrea Ardizzoni, Shirish M Gadgeel, Bushi Wang, Vikram K Chand, Glenwood D Goss
Publikováno v:
Современная онкология, Vol 17, Iss 3, Pp 42-52 (2015)
Background. There is a major unmet need for effective treatments in patients with squamous cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family blocker) with erlotinib (a reversible EGFR tyrosine kinase inhibitor), as
Externí odkaz:
https://doaj.org/article/d2707293f29543479eb0d50d65f683aa
Autor:
Vahit Özmen, Caner Fidaner, Erol Aksaz, Ümit Bayol, İsmet Dede, Erdem Göker, Bahadır M. Güllüoğlu, Abdurrahman Işıkdoğan, Uğur Topal, Mehmet Uhri, Zafer Utkan, Nurullah Zengin, Murat Tuncer
Publikováno v:
European Journal of Breast Health, Vol 5, Iss 3, Pp 125-134 (2009)
Background: Breast cancer is the most commonly seen and cause of cancer deaths in women in most of the developed and developing countries. Breast cancer awareness and organized population based screening programmes have resulted in early diagnosis, r
Externí odkaz:
https://doaj.org/article/f7fcfde069dc4c24a6d05580ecf81a9c
Publikováno v:
Turkish thoracic journal. 23(4)
Epidermal growth factor receptor mutations are the second most common oncogenic driver event in non-small cell lung cancer. We aimed to compare the first generation erlotinib treatment with the second generation afatinib treatment in patients with no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::03a523c309e87cf8c9d3f40f383e4a81
https://pubmed.ncbi.nlm.nih.gov/35848437
https://pubmed.ncbi.nlm.nih.gov/35848437
Autor:
Serdar NazimTurhal, Dogan Uncu, Fulden PerranYumuk, Levent Korkmaz, Hasan Şenol Coşkun, Halil Kavgaci, Erdem Göker, Tamer Yagci, Ahmet Ozet, Fatih Kose, Gülen Akyol, Mutlu Dogan, Mehmet Artac, Irem Bilgetekin, Guldal Esendagli
Purpose Plexin C1 is a transmembrane receptor and plexin C1 overexpression might have role in carcinogenesis. Hepatocellular carcinoma (HCC) has poor prognosis because of its aggressive behavior and limited treatment options, especially in advanced s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::945e3d094a95cf60dbb11350dd9340dc
https://avesis.gazi.edu.tr/publication/details/251b8deb-b096-4097-84de-5067ccae10e5/oai
https://avesis.gazi.edu.tr/publication/details/251b8deb-b096-4097-84de-5067ccae10e5/oai
Autor:
Erkan Kahraman, Erdem Göker
Background: The possible anti-cancer properties of boron, a trace element for humans, have been demonstrated in various experimental and epidemiological studies, although the effects of boron on liver cancer are unclear. In the present study we evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77642ab136e6c91177aa4595b58daab1
https://hdl.handle.net/11454/76701
https://hdl.handle.net/11454/76701
Autor:
Ayfer Haydaroğlu, Levent Akman, Zeynep Özsaran, Necmettin Özdemir, Erdem Göker, Ahmet Aydın Özsaran, Mustafa Cosan Terek, Osman Zekioğlu, Nuri Yildirim, Ulus Ali Sanli, Senem Alanyali
Publikováno v:
Ege Tıp Dergisi. :39-43
Amac: Ege Universitesi Hastanesinde 1992-2017 arasi kanser tani ve tedavisi yapilan 3379 korpus uteri kanserinin epidemiyolojik ve sag kalim ozelliklerini analiz etmek ve sonuclari literaturle karsilastirmaktir. Gerec ve Yontem: Ege Universitesi Kans
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9979b2d29fd7186c8ae8a15651ca19f2
https://doi.org/10.19161/etd.669672
https://doi.org/10.19161/etd.669672
Autor:
Serdar Özkök, Ali Özdil, Ayşe Gül Ergönül, Tevfik İlker Akçam, Alpaslan Çakan, Deniz Nart, Gürsel Çok, Ufuk Çağirici, Ayşe Caner, Kutsal Turhan, Erdem Göker
Publikováno v:
Ege Tıp Dergisi. :140-144
Amac: Malign plevral mazotelyoma (MPM) kotu prognozlu olumcul bir hastaliktir. MPM icin ortalama sag kalim 4-18 ay arasinda degismektedir. MPM’de tum tedavilere ragmen yuksek mortalite goruldugunden, elimizdeki bilinen tum tedaviler hastalara uygul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e866cf350167a6a827ab07b34d33c84
https://doi.org/10.19161/etd.669385
https://doi.org/10.19161/etd.669385
Autor:
Nuri Yildirim, Ayfer Haydaroglu, Zeynep Özsaran, Osman Zekioglu, Levent Akman, Ayşegül Besler, Duygu Guzel, Ulus Ali Sanli, Mustafa Cosan Terek, Ahmet Aydın Özsaran, Necmettin Özdemir, Erdem Göker
Publikováno v:
Ege Tıp Dergisi. :44-49
Amac: Ege Universitesi Hastanesinde 1992-2017 arasi tani alan ve tedavisi yapilan 1770 over kanserli olgunun epidemiyolojik ve sag kalim ozelliklerini analiz etmek ve sonuclarini literaturle karsilastirmaktir. Gerec ve Yontem: Ege Universitesi Kanser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f68197999a8351ae4a9be33f0fbe46cc
https://doi.org/10.19161/etd.669376
https://doi.org/10.19161/etd.669376